医学
免疫抑制
间充质干细胞
移植
器官移植
细胞疗法
人口
临床试验
骨髓
肺
肾移植
间质细胞
免疫学
病理
细胞
外科
内科学
生物
环境卫生
遗传学
作者
Sonia Fiori,Giuseppe Remuzzi,Federica Casiraghi
标识
DOI:10.1097/mot.0000000000000716
摘要
The available clinical studies in kidney, liver and lung transplantation indicate that autologous and allogeneic MSC therapy from different sources are safe. Now it's time to focus on well-designed efficacy clinical trials, possibly including extensive immunomonitoring.
科研通智能强力驱动
Strongly Powered by AbleSci AI